{"count": 187, "results": [{"_id": "35685234", "pmid": 35685234, "pmcid": "PMC9137235", "title": "Probiotic Lactobacillus plantarum may reduce cardiovascular risk: An experimental study", "journal": "ARYA Atheroscler", "authors": ["Neverovskyi A", "Chernyavskyi V", "Shypulin V", "Hvozdetska L", "Tishchenko V", "Nechypurenko T", "Mikhn Ova N"], "date": "2021-07-01T00:00:00Z", "doi": "10.22122/arya.v17i0.2156", "meta_date_publication": "2021 Jul", "meta_volume": "17", "meta_issue": "4", "meta_pages": "1-10", "score": 50278.91, "text_hl": "Participants were of both sexes, 40-74 years-of-age, and had @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@. The participants were divided into 2 groups; the treatment group (n = 41) received a combination of @SPECIES_1590 @@@Lactobacillus plantarum@@@ and @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ 20 mg once a day, and the control group (n = 36) received @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ 20 mg once a day. ", "citations": {"NLM": "Neverovskyi A, Chernyavskyi V, Shypulin V, Hvozdetska L, Tishchenko V, Nechypurenko T, Mikhn Ova N. Probiotic Lactobacillus plantarum may reduce cardiovascular risk: An experimental study ARYA Atheroscler. 2021 Jul;17(4):1-10. PMID: 35685234", "BibTeX": "@article{35685234, title={Probiotic Lactobacillus plantarum may reduce cardiovascular risk: An experimental study}, author={Neverovskyi A and Chernyavskyi V and Shypulin V and Hvozdetska L and Tishchenko V and Nechypurenko T and Mikhn Ova N}, journal={ARYA Atheroscler}, volume={17}, number={4}, pages={1-10}}"}}, {"_id": "34495217", "pmid": 34495217, "pmcid": "PMC8395802", "title": "Uso de Estatinas Melhora a Protecao Cardiometabolica Promovida pelo Treinamento Fisico em Ambiente Aquatico: Um Ensaio Clinico Randomizado", "journal": "Arq Bras Cardiol", "authors": ["Costa RR", "Vieira AF", "Coconcelli L", "Fagundes AO", "Buttelli ACK", "Pereira LF", "Stein R", "Kruel LFM"], "date": "2021-08-01T00:00:00Z", "doi": "10.36660/abc.20200197", "meta_date_publication": "2021 Aug", "meta_volume": "117", "meta_issue": "2", "meta_pages": "270-278", "score": 50277.875, "text_hl": "Thus, this study aimed to analyze the influence of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ use on @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@lipid@@@ adaptations arising from water-based aerobic and resistance training in elderly @SPECIES_9606 @@@women@@@ with @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@. ", "citations": {"NLM": "Costa RR, Vieira AF, Coconcelli L, Fagundes AO, Buttelli ACK, Pereira LF, Stein R, Kruel LFM. Uso de Estatinas Melhora a Protecao Cardiometabolica Promovida pelo Treinamento Fisico em Ambiente Aquatico: Um Ensaio Clinico Randomizado Arq Bras Cardiol. 2021 Aug;117(2):270-278. PMID: 34495217", "BibTeX": "@article{34495217, title={Uso de Estatinas Melhora a Protecao Cardiometabolica Promovida pelo Treinamento Fisico em Ambiente Aquatico: Um Ensaio Clinico Randomizado}, author={Costa RR and Vieira AF and Coconcelli L and Fagundes AO and Buttelli ACK and Pereira LF and Stein R and Kruel LFM}, journal={Arq Bras Cardiol}, volume={117}, number={2}, pages={270-278}}"}}, {"_id": "35983393", "pmid": 35983393, "pmcid": "PMC9376206", "title": "Evaluation of the Antinociceptive Action of Simvastatin in Mice", "journal": "Cureus", "authors": ["Katole NT", "Kale JS", "Salankar HV"], "date": "2022-07-16T00:00:00Z", "doi": "10.7759/cureus.26910", "meta_date_publication": "2022 Jul", "meta_volume": "14", "meta_issue": "7", "meta_pages": "e26910", "score": 50277.72, "text_hl": "Similarly, it inhibits @DISEASE_Pain @DISEASE_MESH:D010146 @@@inflammatory pain@@@ more predominantly than @DISEASE_Urinary_Bladder_Neurogenic @DISEASE_MESH:D001750 @@@neurogenic@@@, and hence @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ can be used in @DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammatory@@@ conditions like @DISEASE_Arthritis_Rheumatoid @DISEASE_MESH:D001172 @@@rheumatoid arthritis@@@ and @DISEASE_Osteoarthritis @DISEASE_MESH:D010003 @@@osteoarthritis@@@ particularly when there is coexisting @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@.", "citations": {"NLM": "Katole NT, Kale JS, Salankar HV. Evaluation of the Antinociceptive Action of Simvastatin in Mice Cureus. 2022 Jul;14(7):e26910. PMID: 35983393", "BibTeX": "@article{35983393, title={Evaluation of the Antinociceptive Action of Simvastatin in Mice}, author={Katole NT and Kale JS and Salankar HV}, journal={Cureus}, volume={14}, number={7}, pages={e26910}}"}}, {"_id": "35966518", "pmid": 35966518, "pmcid": "PMC9363636", "title": "The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis", "journal": "Front Cardiovasc Med", "authors": ["Zhang J", "Wang X", "Tian W", "Wang T", "Jia J", "Lai R", "Wang T", "Zhang Z", "Song L", "Ju J", "Xu H"], "date": "2022-07-27T00:00:00Z", "doi": "10.3389/fcvm.2022.936817", "meta_date_publication": "2022", "meta_volume": "9", "meta_issue": "", "meta_pages": "936817", "score": 50274.887, "text_hl": "@CHEMICAL_Rosuvastatin_Calcium @CHEMICAL_MESH:D000068718 @@@Rosuvastatin@@@ 10 mg 6 m Oral hypoglycemic agents   Robert, 2011  Poland Mixed @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@Dyslipidemia@@@ and T2DM 96 53 57.46 @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ 40 mg vs. ", "citations": {"NLM": "Zhang J, Wang X, Tian W, Wang T, Jia J, Lai R, Wang T, Zhang Z, Song L, Ju J, Xu H. The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis Front Cardiovasc Med. 2022;9():936817. PMID: 35966518", "BibTeX": "@article{35966518, title={The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis}, author={Zhang J and Wang X and Tian W and Wang T and Jia J and Lai R and Wang T and Zhang Z and Song L and Ju J and Xu H}, journal={Front Cardiovasc Med}, volume={9}, pages={936817}}"}}, {"_id": "33898117", "pmid": 33898117, "pmcid": "PMC8059484", "title": "Vitiligo: The Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator", "journal": "Cureus", "authors": ["Verma D", "Hussain K", "Namiq KS", "Firoz A", "Bouchama M", "Raza M", "Haris M", "Khan S"], "date": "2021-03-22T00:00:00Z", "doi": "10.7759/cureus.14029", "meta_date_publication": "2021 Mar 22", "meta_volume": "13", "meta_issue": "3", "meta_pages": "e14029", "score": 50268.184, "text_hl": "@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ is a potent hypolipidemic drug that also possesses immunomodulating properties and is a common drug used in @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@ and @DISEASE_Cardiovascular_Diseases @DISEASE_MESH:D002318 @@@cardiovascular diseases@@@. ", "citations": {"NLM": "Verma D, Hussain K, Namiq KS, Firoz A, Bouchama M, Raza M, Haris M, Khan S. Vitiligo: The Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator Cureus. 2021 Mar 22;13(3):e14029. PMID: 33898117", "BibTeX": "@article{33898117, title={Vitiligo: The Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator}, author={Verma D and Hussain K and Namiq KS and Firoz A and Bouchama M and Raza M and Haris M and Khan S}, journal={Cureus}, volume={13}, number={3}, pages={e14029}}"}}, {"_id": "32277945", "pmid": 32277945, "title": "Statin downregulation of miR-652-3p protects endothelium from dyslipidemia by promoting ISL1 expression.", "journal": "Metabolism", "authors": ["Liang L", "Su W", "Zhou L", "Cao Y", "Zhou X", "Liu S", "Zhao Y", "Ding X", "Wang Q", "Zhang H"], "date": "2020-06-01T00:00:00Z", "doi": "10.1016/j.metabol.2020.154226", "meta_date_publication": "2020 Jun", "meta_volume": "107", "meta_issue": "", "meta_pages": "154226", "score": 50266.64, "text_hl": "The @SPECIES_10116 @@@rat@@@ model of @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@ exhibited a similar pattern of miR-652-3p upregulation, attenuated @GENE_ISL1 @GENE_64444 @@@ISL1@@@ protein levels, decreased @GENE_NOS3 @GENE_24600 @@@eNOS@@@ activation, and decreased NO production, effects mitigated by @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@. ", "citations": {"NLM": "Liang L, Su W, Zhou L, Cao Y, Zhou X, Liu S, Zhao Y, Ding X, Wang Q, Zhang H. Statin downregulation of miR-652-3p protects endothelium from dyslipidemia by promoting ISL1 expression. Metabolism. 2020 Jun;107():154226. PMID: 32277945", "BibTeX": "@article{32277945, title={Statin downregulation of miR-652-3p protects endothelium from dyslipidemia by promoting ISL1 expression.}, author={Liang L and Su W and Zhou L and Cao Y and Zhou X and Liu S and Zhao Y and Ding X and Wang Q and Zhang H}, journal={Metabolism}, volume={107}, pages={154226}}"}}, {"_id": "36346030", "pmid": 36346030, "title": "Simvastatin and non-segmental vitiligo: A new potential treatment option?", "journal": "Dermatol Ther", "authors": ["Shaker ESE", "Allam SH", "Mabrouk MM", "Elgharbawy NM", "Salaam SFA"], "date": "2022-12-01T00:00:00Z", "doi": "10.1111/dth.15969", "meta_date_publication": "2022 Dec", "meta_volume": "35", "meta_issue": "12", "meta_pages": "e15969", "score": 50264.934, "text_hl": "Negative moderate correlation was found between the decrease in VIDA and duration of disease (r = -0.562, p < 0.001). @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ 80 mg daily could be a helpful treatment for @DISEASE_Vitiligo @DISEASE_MESH:D014820 @@@NSV@@@ @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@, controlling the @DISEASE_Vitiligo @DISEASE_MESH:D014820 @@@vitiligo@@@ activity and protecting against the hazardous effects of @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@. ", "citations": {"NLM": "Shaker ESE, Allam SH, Mabrouk MM, Elgharbawy NM, Salaam SFA. Simvastatin and non-segmental vitiligo: A new potential treatment option? Dermatol Ther. 2022 Dec;35(12):e15969. PMID: 36346030", "BibTeX": "@article{36346030, title={Simvastatin and non-segmental vitiligo: A new potential treatment option?}, author={Shaker ESE and Allam SH and Mabrouk MM and Elgharbawy NM and Salaam SFA}, journal={Dermatol Ther}, volume={35}, number={12}, pages={e15969}}"}}, {"_id": "37986006", "pmid": 37986006, "pmcid": "PMC10662842", "title": "Attenuation of estrogen and its receptors in the post-menopausal stage exacerbates dyslipidemia and leads to cognitive impairment", "journal": "Mol Brain", "authors": ["Meng Q", "Chao Y", "Zhang S", "Ding X", "Feng H", "Zhang C", "Liu B", "Zhu W", "Li Y", "Zhang Q", "Tong H", "Wu L", "Bian H"], "date": "2023-11-20T00:00:00Z", "doi": "10.1186/s13041-023-01068-0", "meta_date_publication": "2023 Nov 20", "meta_volume": "16", "meta_issue": "1", "meta_pages": "80", "score": 50262.832, "text_hl": "@CHEMICAL_Estradiol @CHEMICAL_MESH:D004958 @@@beta-estradiol@@@ or @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ effectively attenuated @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@-induced @DISEASE_Malformations_of_Cortical_Development_Group_I @DISEASE_MESH:D065703 @@@neuronal apoptosis@@@ via upregulation of ERs, whereas @GENE_ESR1 @GENE_13982 @@@ERalpha@@@, @GENE_ESR2 @GENE_2100 @@@ERbeta@@@ and @GENE_GPER1 @GENE_2852 @@@GPER@@@ inhibitors together abolished the protective effect of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ on @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@lipid@@@-induced @DISEASE_Malformations_of_Cortical_Development_Group_I @DISEASE_MESH:D065703 @@@neuronal apoptosis@@@. ", "citations": {"NLM": "Meng Q, Chao Y, Zhang S, Ding X, Feng H, Zhang C, Liu B, Zhu W, Li Y, Zhang Q, Tong H, Wu L, Bian H. Attenuation of estrogen and its receptors in the post-menopausal stage exacerbates dyslipidemia and leads to cognitive impairment Mol Brain. 2023 Nov 20;16(1):80. PMID: 37986006", "BibTeX": "@article{37986006, title={Attenuation of estrogen and its receptors in the post-menopausal stage exacerbates dyslipidemia and leads to cognitive impairment}, author={Meng Q and Chao Y and Zhang S and Ding X and Feng H and Zhang C and Liu B and Zhu W and Li Y and Zhang Q and Tong H and Wu L and Bian H}, journal={Mol Brain}, volume={16}, number={1}, pages={80}}"}}, {"_id": "33049128", "pmid": 33049128, "pmcid": "PMC10528624", "title": "Lipid profile and response to statin therapy in patients with hypopituitarism", "journal": "Arch Endocrinol Metab", "authors": ["Rissetti G", "Zeni D", "Ongaratti BR", "Pereira-Lima JFS", "Rech CGSL", "da Costa Oliveira M"], "date": "2021-11-01T00:00:00Z", "doi": "10.20945/2359-3997000000292", "meta_date_publication": "2021 Nov 1", "meta_volume": "64", "meta_issue": "6", "meta_pages": "673-678", "score": 50258.516, "text_hl": "The specific choice for @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ in our study was based on the extensive use of this drug to treat @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@. ", "citations": {"NLM": "Rissetti G, Zeni D, Ongaratti BR, Pereira-Lima JFS, Rech CGSL, da Costa Oliveira M. Lipid profile and response to statin therapy in patients with hypopituitarism Arch Endocrinol Metab. 2021 Nov 1;64(6):673-678. PMID: 33049128", "BibTeX": "@article{33049128, title={Lipid profile and response to statin therapy in patients with hypopituitarism}, author={Rissetti G and Zeni D and Ongaratti BR and Pereira-Lima JFS and Rech CGSL and da Costa Oliveira M}, journal={Arch Endocrinol Metab}, volume={64}, number={6}, pages={673-678}}"}}, {"_id": "32405982", "pmid": 32405982, "title": "Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery.", "journal": "AAPS PharmSciTech", "authors": ["Rahamathulla M", "H V G", "Veerapu G", "Hani U", "Alhamhoom Y", "Alqahtani A", "Moin A"], "date": "2020-05-13T00:00:00Z", "doi": "10.1208/s12249-020-01666-4", "meta_date_publication": "2020 May 13", "meta_volume": "21", "meta_issue": "4", "meta_pages": "129", "score": 50258.227, "text_hl": "...@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ a @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@cholesterol@@@-lowering agent used to treat @DISEASE_Hypercholesterolemia @DISEASE_MESH:D006937 @@@hypercholesterolemia@@@, @DISEASE_Coronary_Disease @DISEASE_MESH:D003327 @@@coronary heart disease@@@, and @<m>DISEASE_Dyslipidemias</m> @DISEASE_MESH:D050171 @@@dyslipidemia@@@. ", "citations": {"NLM": "Rahamathulla M, H V G, Veerapu G, Hani U, Alhamhoom Y, Alqahtani A, Moin A. Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery. AAPS PharmSciTech. 2020 May 13;21(4):129. PMID: 32405982", "BibTeX": "@article{32405982, title={Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery.}, author={Rahamathulla M and H V G and Veerapu G and Hani U and Alhamhoom Y and Alqahtani A and Moin A}, journal={AAPS PharmSciTech}, volume={21}, number={4}, pages={129}}"}}]}